FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025162893> ?p ?o ?g. }

• W2025162893 endingPage "1453." @default.
• W2025162893 startingPage "1447" @default.
• W2025162893 abstract "Background Halothane increases bleeding time and suppresses platelet aggregation in vivo and in vitro. A previous study by the authors suggests that halothane inhibits platelet aggregation by reducing thromboxane (TX) A2 receptor-binding affinity. However, no studies of the effects of sevoflurane on platelet aggregation have been published. Methods The effects of sevoflurane, halothane, and isoflurane were examined at doses of 0.13-1.4 mM. Human platelet aggregation was induced by adenosine diphosphate, epinephrine, arachidonic acid, prostaglandin G2, and a TXA2 agonist ([+]-9, 11-epithia-11, 12-methano-TXA2, STA2) and measured by aggregometry. Platelet TXB2 levels were measured by radioimmunoassay, and the ligand-binding characteristics of the TXA2 receptors were examined by Scatchard analysis using a [3H]-labeled TXA2 receptor antagonist (5Z-7-(3-endo-([ring-4-[3H] phenyl) sulphonylamino-[2.2.1.] bicyclohept-2-exo-yl) heptenoic acid, [3H]S145). Results Isoflurane (0.28-0.84 mM) did not significantly affect platelet aggregation induced by adenosine diphosphate and epinephrine. Sevoflurane (0.13-0.91 mM) and halothane (0.49-1.25 mM) inhibited secondary platelet aggregation induced by adenosine diphosphate (1-10 microM) and epinephrine (1-10 microM) without altering primary aggregation. Sevoflurane (0.13 mM) also inhibited arachidonic acid-induced aggregation, but not that induced by prostaglandin G2 or STA2, although halothane (0.49 mM) inhibited the latter. Sevoflurane (3 mM) did not affect the binding of [3H]S145 to platelets, whereas halothane (3.3 mM) suppressed it strongly. Sevoflurane (0.26 mM) and halothane (0.98 mM) strongly suppressed TXB2 formation by arachidonic acid-stimulated platelets. Conclusions The findings that sevoflurane suppressed the effects of arachidonic acid, but not those of prostaglandin G2 and STA2, suggest strongly that sevoflurane inhibited TXA2 formation by suppressing cyclooxygenase activity. Halothane appeared to suppress both TXA2 formation and binding to its receptors. Sevoflurane has strong antiaggregatory effects at subanesthetic concentrations (greater than 0.13 mM; i.e., approximately 0.5 vol/%), whereas halothane has similar effects at somewhat greater anesthetic concentrations (0.49 mM; i.e., approximately 0.54 vol/%). Isoflurane at clinical concentration (0.84 mM; i.e., approximately 1.82 vol/%) does not affect platelet aggregation significantly." @default.
• W2025162893 created "2016-06-24" @default.
• W2025162893 creator A5006455541 @default.
• W2025162893 creator A5007296792 @default.
• W2025162893 creator A5016507067 @default.
• W2025162893 creator A5024624058 @default.
• W2025162893 creator A5035947580 @default.
• W2025162893 creator A5037342903 @default.
• W2025162893 creator A5048368425 @default.
• W2025162893 creator A5054365571 @default.
• W2025162893 creator A5071185972 @default.
• W2025162893 date "1996-12-01" @default.
• W2025162893 modified "2023-09-26" @default.
• W2025162893 title "Sevoflurane Inhibits Human Platelet Aggregation and Thromboxane A2Formation, Possibly by Suppression of Cyclooxygenase Activity" @default.
• W2025162893 cites W1604451973 @default.
• W2025162893 cites W1972287726 @default.
• W2025162893 cites W1975434667 @default.
• W2025162893 cites W1982054401 @default.
• W2025162893 cites W1993719781 @default.
• W2025162893 cites W1994961449 @default.
• W2025162893 cites W2005159487 @default.
• W2025162893 cites W2029577335 @default.
• W2025162893 cites W2053985236 @default.
• W2025162893 cites W2087967501 @default.
• W2025162893 cites W2129387053 @default.
• W2025162893 cites W2418585365 @default.
• W2025162893 cites W2439367125 @default.
• W2025162893 doi "https://doi.org/10.1097/00000542-199612000-00027" @default.
• W2025162893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8968193" @default.
• W2025162893 hasPublicationYear "1996" @default.
• W2025162893 type Work @default.
• W2025162893 sameAs 2025162893 @default.
• W2025162893 citedByCount "82" @default.
• W2025162893 countsByYear W20251628932012 @default.
• W2025162893 countsByYear W20251628932013 @default.
• W2025162893 countsByYear W20251628932014 @default.
• W2025162893 countsByYear W20251628932015 @default.
• W2025162893 countsByYear W20251628932016 @default.
• W2025162893 countsByYear W20251628932019 @default.
• W2025162893 countsByYear W20251628932020 @default.
• W2025162893 countsByYear W20251628932021 @default.
• W2025162893 countsByYear W20251628932022 @default.
• W2025162893 crossrefType "journal-article" @default.
• W2025162893 hasAuthorship W2025162893A5006455541 @default.
• W2025162893 hasAuthorship W2025162893A5007296792 @default.
• W2025162893 hasAuthorship W2025162893A5016507067 @default.
• W2025162893 hasAuthorship W2025162893A5024624058 @default.
• W2025162893 hasAuthorship W2025162893A5035947580 @default.
• W2025162893 hasAuthorship W2025162893A5037342903 @default.
• W2025162893 hasAuthorship W2025162893A5048368425 @default.
• W2025162893 hasAuthorship W2025162893A5054365571 @default.
• W2025162893 hasAuthorship W2025162893A5071185972 @default.
• W2025162893 hasConcept C126322002 @default.
• W2025162893 hasConcept C134018914 @default.
• W2025162893 hasConcept C170493617 @default.
• W2025162893 hasConcept C181199279 @default.
• W2025162893 hasConcept C185592680 @default.
• W2025162893 hasConcept C2775859304 @default.
• W2025162893 hasConcept C2776359302 @default.
• W2025162893 hasConcept C2776785769 @default.
• W2025162893 hasConcept C2776932660 @default.
• W2025162893 hasConcept C2776991684 @default.
• W2025162893 hasConcept C2777361909 @default.
• W2025162893 hasConcept C2777399203 @default.
• W2025162893 hasConcept C2778078955 @default.
• W2025162893 hasConcept C2778938600 @default.
• W2025162893 hasConcept C2779689624 @default.
• W2025162893 hasConcept C2780664492 @default.
• W2025162893 hasConcept C2781024287 @default.
• W2025162893 hasConcept C2781453256 @default.
• W2025162893 hasConcept C2993802102 @default.
• W2025162893 hasConcept C42219234 @default.
• W2025162893 hasConcept C51603380 @default.
• W2025162893 hasConcept C55493867 @default.
• W2025162893 hasConcept C71924100 @default.
• W2025162893 hasConcept C89560881 @default.
• W2025162893 hasConcept C98274493 @default.
• W2025162893 hasConceptScore W2025162893C126322002 @default.
• W2025162893 hasConceptScore W2025162893C134018914 @default.
• W2025162893 hasConceptScore W2025162893C170493617 @default.
• W2025162893 hasConceptScore W2025162893C181199279 @default.
• W2025162893 hasConceptScore W2025162893C185592680 @default.
• W2025162893 hasConceptScore W2025162893C2775859304 @default.
• W2025162893 hasConceptScore W2025162893C2776359302 @default.
• W2025162893 hasConceptScore W2025162893C2776785769 @default.
• W2025162893 hasConceptScore W2025162893C2776932660 @default.
• W2025162893 hasConceptScore W2025162893C2776991684 @default.
• W2025162893 hasConceptScore W2025162893C2777361909 @default.
• W2025162893 hasConceptScore W2025162893C2777399203 @default.
• W2025162893 hasConceptScore W2025162893C2778078955 @default.
• W2025162893 hasConceptScore W2025162893C2778938600 @default.
• W2025162893 hasConceptScore W2025162893C2779689624 @default.
• W2025162893 hasConceptScore W2025162893C2780664492 @default.
• W2025162893 hasConceptScore W2025162893C2781024287 @default.
• W2025162893 hasConceptScore W2025162893C2781453256 @default.
• W2025162893 hasConceptScore W2025162893C2993802102 @default.
• W2025162893 hasConceptScore W2025162893C42219234 @default.
• W2025162893 hasConceptScore W2025162893C51603380 @default.

• next